Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
COVID19 Prevention & Care; A Cancer Specific Guideline.
Motlagh A, Yamrali M, Azghandi S, Azadeh P, Vaezi M, Ashrafi F, Zendehdel K, Mirzaei H, Basi A, Rakhsha A, Seifi S, Tabatabaeefar M, Elahi A, Pirjani P, Moadab Shoar L, Nadarkhani F, Khoshabi M, Bahar M, Esfahani F, Fudazi H, Samiei F, Farazmand B, Ahmari A, Vand Rajabpour M, Janbabaei G, Raisi A, Ostovar A, Malekzadeh R. Motlagh A, et al. Among authors: seifi s. Arch Iran Med. 2020 Apr 1;23(4):255-264. doi: 10.34172/aim.2020.07. Arch Iran Med. 2020. PMID: 32271599 Free article.
The Frequency of Epidermal Growth Factor Receptor (EGFR) Mutation in Patients with Lung Adenocarcinoma Referred to a Lung Diseases Hospital; A Cross-Sectional Study from Iran.
Mohammadi S, Rezaei M, Shojaeian F, Pourabdollah M, Mohammadi Ziazi L, Seifi S, Doroudinia A, Salimi B, Khosravi A, Farhangnasab MA. Mohammadi S, et al. Among authors: seifi s. Iran J Pathol. 2022 Spring;17(2):159-165. doi: 10.30699/IJP.2022.533427.2673. Epub 2022 Feb 20. Iran J Pathol. 2022. PMID: 35463723 Free PMC article.
Renal Disorders in Pulmonary Sarcoidosis Patients.
Yassari F, Kiani A, Taghavi K, Abdi E, Emami H, Seifi S, Abedini A. Yassari F, et al. Among authors: seifi s. Iran J Kidney Dis. 2019 Jan;13(1):21-26. Iran J Kidney Dis. 2019. PMID: 30851715 Free article.
Post-Marketing Surveillance of a generic Oxaliplatin (AlvoxalⓇ) in Iranian Patients with Cancer.
Shahi F, Gorji M, Payandeh M, Rezvani H, Vaezi M, Seifi S, Baari A, Khalili-Dizaji R, Hashemi SM, Salimi S, Kamranzadeh H, Shazad B, Salari S, Dameshghi DO, Sarkheil M, Mirzania M, Anjidani N. Shahi F, et al. Among authors: seifi s. Curr Ther Res Clin Exp. 2021 Nov 29;96:100657. doi: 10.1016/j.curtheres.2021.100657. eCollection 2022. Curr Ther Res Clin Exp. 2021. PMID: 35024073 Free PMC article.
National Research Institute of Tuberculosis and Lung Disease (NRITLD) Protocol for the Treatment of Patients with COVID-19.
Mirenayat MS, Abedini A, Kiani A, Eslaminejad A, Adimi Naghan P, Malekmohammad M, Heshmatnia J, Nadji SA, Idani E, Zahiri R, Lookzadeh S, Sheikhzade H, Dastan F, Porabdollah Toutkaboni M, Rezaei MS, Askari E, Tabarsi P, Marjani M, Moniri A, Hashemian SMR, Farzanegan B, Abtahian Z, Yassari F, Mansouri N, Mansouri D, Vasheghani M, Mansourafshar B, Mokhber Dezfoli M, Soleimani S, Seifi S, Naghashzadeh F, Fakharian A, Varahram M, Jamaati H, Zali A, Velayati AA. Mirenayat MS, et al. Among authors: seifi s. Iran J Pharm Res. 2022 Mar 30;21(1):e123947. doi: 10.5812/ijpr.123947. eCollection 2022 Dec. Iran J Pharm Res. 2022. PMID: 35765502 Free PMC article.
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
Dastan F, Saffaei A, Haseli S, Marjani M, Moniri A, Abtahian Z, Abedini A, Kiani A, Seifi S, Jammati H, Hashemian SMR, Pourabdollah Toutkaboni M, Eslaminejad A, Heshmatnia J, Sadeghi M, Nadji SA, Dastan A, Baghaei P, Varahram M, Yousefian S, Salamzadeh J, Tabarsi P. Dastan F, et al. Among authors: seifi s. Int Immunopharmacol. 2020 Nov;88:106869. doi: 10.1016/j.intimp.2020.106869. Epub 2020 Aug 4. Int Immunopharmacol. 2020. PMID: 32889241 Free PMC article. Clinical Trial.
Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form.
Tabarsi P, Vahidi H, Saffaei A, Hashemian SMR, Jammati H, Daraei B, Mahboubi A, Kobarfard F, Marjani M, Moniri A, Abtahian Z, Abedini A, Eslaminejad A, Heshmatnia J, Mirenayat MS, Fakharian A, Seifi S, Sadeghi M, Dastan A, Haseli S, Nadji SA, Eskandari R, Yousefian S, Varahram M, Zali A, Velayati AA, Dastan F. Tabarsi P, et al. Among authors: seifi s. Iran J Pharm Res. 2021 Fall;20(4):1-8. doi: 10.22037/ijpr.2021.115510.15401. Iran J Pharm Res. 2021. PMID: 35194422 Free PMC article.
151 results